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Curcumin is an important nutraceutical that has enormous potential for a variety of diseases, but the medicinal properties of
curcumin cannot be utilized due to its low in vivo bioavailability. Therefore, in view of the foregoing, there is an extensive need for
combinatorial extract “curcumin with piperine and quercetin” which may enhance bioavailability of oral curcumin by inhibiting
the enzymes responsible for the metabolism of curcumin. Thus, the present study investigated the eﬀect of combinatorial extract
of curcumin on obesity, glucose intolerance, and oxidative stress in high fat diet and low-dose streptozotocin-induced rats. Oral
administration of combinatorial extract for 28 days signiﬁcantly (P<0.05) reduced PGL (64.84%), PTG (88.94%), LDL (26.38%)
and PTC (50.23%) levels, respectively and improved glucose tolerance (P<0.05) signiﬁcantly to exogenously administered
glucose (2g/kg) at 60, 90, and 120min interval on OGTT. The results for antioxidant potential indicate that at 100mg/kg dose
of combinatorial extract of curcumin signiﬁcantly prevented the high-fat diet and low-dose streptozotocin-induced changes in the
oxidative stress parameters (P<0.01) which supports popular medicinal uses of this combinatorial extract as antihyperglycemic
andhypolipidemicandislikelytobringthispromisingnaturalproducttotheforefrontoftherapeuticagentsintheinthetreatment
of “metabolic syndrome”.
1.Introduction
Metabolic syndrome, a concurrence of disorders including
obesity, insulin resistance, dyslipidemia, and hypertension,
has gained importance because of its association with
subsequentdevelopmentofcardiovasculardiseaseandtype2
diabetes [1]. In contemporary times, the metabolic disorder
is becoming an alarming concern for the developed as
well as the developing world. The prevalence of metabolic
syndrome is increasing worldwide and is a growing threat
to global health, since it accounts for 6-7% of all-cause
mortality.Peoplewithmetabolicsyndromearetwiceaslikely
to die from heart attack or stroke compared with people
without the syndrome and has a ﬁve fold greater risk of
developing type 2 diabetes [2, 3]I ti so n eo ft h eb i g g e s t
health concerns of our time as it aﬀects more than one-third
of the population, and it will continue to plaque the world
at an alarming rate. Diet, exercise, and nutritional supple-
mentation play a key role for maintaining a healthy lifestyle
and well being of an individual, especially related to cardio-
vascular diseases, despite remarkable advances in medicine
and pharmaceutical drug development. Thus, the current
scenario possesses a need to address and focus our research
on nutraceuticals and its role in metabolic syndrome.
Curcumin, an important nutraceutical obtained from the
rootoftheplant CurcumalongaLinn(familyZingiberaceae),
is a perennial herb that has immense medicinal properties
and is a nontoxic, highly promising natural compound
having a wide spectrum of biological functions such as anti-
inﬂammatory [4], hepato- and nephro-protective [5, 6],2 ISRN Pharmacology
antioxidant, [7–9] antimicrobial, [10] anticarcinogenic [11],
and thrombosis-suppressing properties [12, 13]. Although
Curcumalongahasbeeninvestigatedforitsvariousmedicinal
properties, detailed studies on its antidiabetic, antioxidant
potential, and lipid peroxidation level in diabetic rats are still
lacking as the medicinal properties of curcumin cannot be
utilized due to its limited aqueous solubility and degradation
at alkaline pH which restricts its bioavailability. Therefore,
in view of the foregoing, there is an extensive need for such
combination of curcumin with piperine and quercetin as
piperine is an alkaloid found naturally in plants as Piper
nigrum L, commonly known as black pepper is established
as a bioavailability enhancer of drugs. It is an inhibitor of
glucuronidation metabolism hence increases bioavailability
(serum concentration) of oral curcumin [14], and if a
second bioavailability enhancer such as quercetin is added,
a ni n c r e a s ei na b s o r p t i o ni sp o s s i b l et oag r e a t e re x t e n ta si t
aids in the inhibition of metabolic conversion of curcumin.
Thus, the present study was envisaged to determine the
eﬀect of combinatorial extract “curcumin with piperine and
quercetin” on glucose intolerance and oxidative stress in
high-fat diet and low-dose streptozotocin-induced rats. In
addition the antiobesity eﬀe c to fc o m b i n a t o r i a le x t r a c to f
curcumin on diet-induced changes in body weight, plasma
glucose, triglyceride cholesterol, and low-density lipoprotein
(LDL) were also determined.
2.MaterialsandMethods
2.1. Animals. Albino female wistar rats (11 weeks old) were
used in the present investigation. The animals were main-
tained in polypropylene cage in the Departmental Animal
House Facility, with 12h light: 12h dark cycle. All the ani-
mals were kept under laboratory condition (temperature 25
± 2◦C; relative humidity 75%±5%) for an acclimatization
period of 7 days before carrying out the experiments. During
theexperimentsanimalswereprovidedwithstandardrodent
pellet diet (Amrut laboratory animal feed, Maharashtra),
and ﬁltered water was provided ad libitum.T h ee x p e r i m e n t
was approved by Animal ethical committee, Department of
Pharmacology, School of Pharmacy & Technology Manage-
ment, Narsee Monjee Institute of Management and Studies,
Mumbai, and conducted according to the guidelines of
Committee for the Purpose of Control and Supervision of
Experimentation on Animals, India.
2.2.Drugs. StreptozotocinwaspurchasedfromSigmachem-
icals, USA. Glucose Oxidase kit was purchased from Transa-
sia Biomedicals Limited, Mumbai. All other chemicals were
of analytical grade and obtained from local suppliers.
2.3. Collection and Authentication of Plant Material. The
rhizomes of Curcuma longa Linn, fruits of Piper nigrum
and red onion of Allium cepa were procured in the months
of March–June from the local market of Mumbai, India.
SpecimensampleswereauthenticatedbyDepartmentofRaw
and Crude drug material, National Institute of Science Com-
munication and Information Resource (NISCAIR), New
Delhi. The voucher specimens were deposited in department
for future reference.
2.4. Extraction and Isolation of Active Constituents. Extrac-
tion and isolation of curcuminoid, piperine, and quercetin
from Curcuma longa Linn, piper nigrum and Allium cepa
was done using petroleum ether, chloroform, and ethanol
as a solvent. The identity of the compound was con-
ﬁrmed by its comparison with reference standard using
thin-layer chromatography (TLC). TLC was developed by
using mobile phase, as chloroform:methanol (9:1) for
curcumin, toluene:ethyl acetate (7:3) for piperine, and
chloroform:methanol:toluene (7:3:1) for quercetin. The
Rf value was found to be similar with that of the standard.
2.5. Preparation of Combinatorial Extract of Curcumin.
Combinatorial extract was prepared by suspending cur-
cumin:piperine:quercetin in a ratio (94:1:5) in 5% Gum
Acacia and 0.5% tween 80. Required quantity of gum acacia
was weighed and taken in a mortar. It was triturated with
very little quantity of tween 80 to form slurry. Accurately
weighed quantity of curcumin, piperine, and quercetin was
added to the slurry and trituration continued. The slurry
was transferred to a measuring cylinder, and the volume was
made up with water. The suspension was transferred to a vial
and shaken thoroughly.
2.6. Acute Toxicity Study. The acute toxicity of combination
consisting of curcumin with piperine and quercetin (CPQ)
was evaluated in mice using the OECD guidelines 423 [15].
Swiss albino mice were randomly divided into three groups,
each containing six animals. The combination consisting of
CPQ was administered orally at doses of 500, 1000, and
2,000mg/kg of body weight. Distilled water was adminis-
tered to control group. The general behavior of the mice
wascontinuouslymonitoredfor1hafterdosing,periodically
during the ﬁrst 24h with special attention given during the
ﬁrst 4h, and daily thereafter, for a total of 14 days. Changes
in the normal activity of mice and their body weights were
monitored and the time at which signs of toxicity or death
appeared was recorded.
2.7. Treatment Schedule and High-Fat Diet and Low-Dose
Streptozotocin-Induced Metabolic Abnormalities. After accli-
mation in the laboratory for one week, the rats were divided
into seven groups (weighing 100–150g) to receive the
followingtreatments:group1receiveddrugvehicleonly(5%
Gum Acacia and 0.5% tween 80), (normal control); group2
received single intraperitoneal injection of freshly prepared
solution of streptozocin (STZ) in a dose of 30mg/kg body
weight, (STZ control); group 3 received high-fat diet, (HFD
control); group 4 received high-fat diet and STZ, (HFD +
STZ 30); group 5 received high-fat diet with STZ and treated
with 100mg/kg curcumin alone, (CE-100mg/kg + HFD +
STZ 30); group 6 received high-fat diet with STZ and treated
with combination consisting of curcumin with piperine and
quercetin at the dose of 100mg/kg, (CBE + HFD + STZ 30);
group 7 received high-fat diet with STZ, and treated withISRN Pharmacology 3
50mg/kg of combination consisting of curcumin with
piperine and quercetin, (CBE + HFD + STZ 30). The HFD
was formulated twice a week and stored at 4◦C in the
refrigerator. The extracts were solubilized in 5% Gum Acacia
and 0.5% tween 80 and were administered by oral gavage
from30to60days.Onday30,theanimalswereinjectedwith
single intraperitoneal injection of freshly prepared solution
of STZ in a dose of 30mg/kg body weight dissolved in citrate
buﬀe r( p H4 . 5 ) .T h er a t sw e r ek e p to nt h ea b o v et r e a t m e n t
and were continued to be fed with the high-fat diet until
day 60. A separate group of animals were fed with normal
diet (20g/day/rat) and did not receive streptozocin injection
(nondiabetic control). During this period body weight, feed
and water intake of the animals were also measured initially
as well as estimated at the end of 8 weeks. At the end
of experimental period, all the animals were anesthetized
and blood samples were withdrawn from retro-orbital route,
using heparin as anticoagulant. No signiﬁcant eﬀect of
ether anaesthesia was observed on the plasma parameters
measured.
2.8. Determination of Plasma Metabolic Parameters. Plasma
samples obtained from the rats were used to estimate the
metabolic parameters. Plasma glucose (PGL), triglyceride
(PTG), cholesterol (PTC), high-density lipoprotein (HDL),
and low-density lipoprotein (LDL) were analyzed using sem-
iautomated bioanalyser using commercially available kits.
2.9. Oral Glucose Tolerance Test. At the end of 8 weeks, all
the rats from each group were fasted for 16h before being
subjected to an oral glucose tolerance test (OGTT) by giving
oral glucose load-2g/kg p.o. [16]. The blood was withdrawn
from the retro orbital sinus at 0, 15, 30, 60, 90, and 120min
after the glucose load from all the animals for the estimation
of glucose. The fasting blood glucose levels were estimated
by the procedure as mentioned by the manufacturer of the
kit (Erba Diagnostics, Germany).
2.10. Assessment of Oxidative Stress Parameters
2.10.1. Preparation of Erythrocyte Lysate. Blood was collected
in a vacutainer precoated with anticoagulant. It was cen-
trifugedat3000rpmfor15mininacoolingcentrifuge(4◦C).
Plasma was separated, and the packed cell volume (PCV)
was washed three times with 0.9% sodium chloride (normal
saline). To 0.5mL of 5% suspension of packed cell volume
in saline, 0.5mL of ice cold distilled water was added and
kept aside for 5min at 4◦C. To this, 0.4mL mixture of
chloroform:ethanol (3:5) was added. The contents were
mixed well and centrifuged at 3000rpm for 20min at 4◦C.
The water layer separated was used as erythrocyte lysate.
2.10.2. Estimation of Catalase. Catalase activity was assayed
by the method of Aebi, (1974) [17]. Brieﬂy, the assay mixture
consisted of 1.95mL phosphate buﬀer: 0.05M (pH 7.0)
containing 5mM EDTA, 1mL of hydrogen peroxide (30mM
solution) and 0.05mL erythrocyte lysate in a ﬁnal volume of
3.0mL. Changes in absorbance were recorded 240nm. One
unit of CAT is deﬁned as the number of μ mole of H2O2
decomposed per min at 25◦C.
2.10.3. Estimation of Reduced Glutathione. Glutathione ac-
tivity was assayed by the method of Beutler et al., 1963 [18].
Brieﬂy, the assay mixture consisted of 0.4mL of erythrocyte
lysate in 1.5mL Tris HCl buﬀer (pH 8.00) and 0.25 of
5, 5  dithiobis-(2-nitrobenzoic acid) DTNB was added.
Intensity of the colour was measured at 412nm against
blank. Glutathione in blood was then calculated as μ moles
per gram of hemoglobin.
2.10.4. Estimation of Superoxide Dismutase. Glutathione
activitywasassayedbythemethodofMarklund,(1984)[19].
Brieﬂy, the assay mixture consisted of 0.1mL of erythrocyte
lysate in 2.8mL of Tris HCl buﬀer (50mM) and 0.1mL of
Pyrogallol (30mM). The rate of autoxidation was observed
by measuring change in optical density at 420nm for 2min
was recorded. One unit of SOD is described as the amount of
enzyme required to cause 50% inhibition of pyrogallol auto
oxidation/3mL of assay mixture.
2.10.5. Histopathology Analysis. Liver, kidney, spleen, and
pancreaswereﬁxedimmediately in10%formalinforroutine
histopathological examination. The tissues were embedded
in paraﬃn, and then sectioned, stained with haematoxylin
and eosin and were examined under light microscope.
Histopathological evaluations were performed by patholo-
gist. Photomicrographs of the microscopical sections were
taken with the help of Motic photomicroscope (Canada)
provided with Motic Images plus 2.0 software.
2.11. Statistical Analysis. The diﬀerences among experimen-
tal and control groups were determined using the Graph Pad
INSTAT 3.0 software for Windows. Comparisons among
diﬀerent groups were performed by analysis of variance
using ANOVA test. Signiﬁcant diﬀerence between control
and experimental groups were assessed by student’s t-test.
A l ld a t aa r ee x p r e s s e da sm e a n± standard error of mean
(S.E.M.); P values less than 0.05 were considered to be
signiﬁcant.
3. Results
The present study demonstrates that the rats fed with high-
fat diet combined with low-dose streptozotocin resulted
in signiﬁcant elevation of plasma glucose as evident from
elevated glycemic levels at 30, 60, 90, and 120min after
glucose challenge, compared with the vehicle-treated normal
pellet diet (NPD) control group (P<0.05) and exhibited
the characteristic features of obesity and glucose intolerance
namely increased body weight, hypertriglyceridemia, hyper-
cholesterolemia and impaired glucose tolerance compared
with NPD fed control groups.
3.1. Eﬀect of CPQ on Biochemical Parameters in High-Fat
Diet and Low-Dose Streptozotocin-Induced Diabetic Rats.
The plasma glucose, triglyceride, cholesterol, LDL levels in4 ISRN Pharmacology
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Figure 1: Eﬀect of CPQ on biochemical parameters in high-fat diet
and low-dose streptozotocin-induced diabetic rats. Values are mean
± S.E.M. (N = 6). All the groups were signiﬁcant ∗∗∗P<0.001,
and ∗∗P<0.01 versus control.
high-fat diet and low-dose streptozocin were observed
signiﬁcantly (P<0.001) increased as compared to normal
pellet diet streptozocin treated group (Figure 1). In addition,
treatment of HFD-/STZ-induced hyperglycemia with CPQ
for 28 days in rats signiﬁcantly reduced PGL (64.84%),
PTG (61.16%), LDL (53.98%), and PTC (48.07%) level
as compared to HFD diet diabetic group. Combination
consisting of curcumin with piperine and quercetin (CPQ)
also increased the downregulated plasma level of HDL at a
rate of 15.81% and in a concentration of 100mg/kg.
3.2. Eﬀect of Combination Consisting of Curcumin with
Piperine and Quercetin (CPQ) on Body Weight. No mortality
was observed in any experimental group throughout the
period of investigation. As can be seen from (Figure 2),
feeding on HFD combined with low-dose streptozocin
showed a signiﬁcant (P<0.05) reduction in the body
weight of HFD-fed rats, which was still considerably higher
than NPD-fed rats. However, treatment with CPQ produced
increase in body weight as compared to curcumin alone
treated group, but the body weight gain during the study
was not statistically diﬀerent between HFD and low-dose
streptozocin combined with HFD-treated groups.
3.3. Eﬀect of CPQ on Oral Glucose Intolerance in High-Fat
Diet and Low-Dose Streptozotocin-Induced Diabetic Rats. As
can be seen from (Figure 3), feeding the animal with high-
fat diet and low-dose STZ showed signiﬁcant elevation in
plasma glucose (P<0.001) seen after, just before OGTT
at the end of 8 weeks of feeding (Figure 3). Oral glucose
tolerance test revealed that low-dose streptozocin combined
with HFD-fed rats showed signiﬁcant impairment in glucose
tolerance to exogenously administered glucose (2g/kg) as
evident from elevated glycemic levels at 30, 60, 90, and
120min after glucose challenge, compared with the vehicle-
treated normal pellet diet (NPD) control group (P<0.05).
Treatment with CPQ consisting of curcumin with piperine
and quercetin (50 and 100mg/kg p.o) once daily for 4 weeks
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Figure 2: Eﬀect of CPQ on body weight in high-fat diet and low-
dosestreptozotocininduceddiabeticrats.Valuesaremean ±S.E.M.
(N = 6).
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Figure 3: Eﬀect of CPQ on oral glucose intolerance in high-fat diet
and low-dose streptozotocin-induced diabetic rats. Values are mean
± S.E.M. (N = 6). All the groups were signiﬁcant ∗∗P<0.01, and
∗P<0.05 versus control.
signiﬁcantly (P<0.001) decreased plasma glucose levels
in HFD and low-dose streptozocin-treated diabetic rats.
Furthermore, CPQ signiﬁcantly improved glucose tolerance
(P<0.05)toexogenouslyadministeredglucose(2g/kg)after
60, 90, and 120min interval on OGTT in HFD and low-dose
streptozocin fed rats compared with the untreated control
HFD and low-dose streptozocin fed rats.
3.4. Eﬀect of CPQ on Oxidative Stress Parameters in High-
Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats.
Treatment with combination consisting of curcumin with
piperine and quercetin (CPQ) showed signiﬁcant changes
in catalase, glutathione, and superoxide dismutase (SOD)
levels in diabetic rats. The activity of catalase,GSH, and SOD
was decreased signiﬁcantly (P<0.01) in high-fat diet and
low-dose streptozocin as compared to normal control group
(Table 1). The decreased levels of antioxidant enzymes inISRN Pharmacology 5
Table 1: Eﬀect of CPQ extract on oxidative stress parameters in high-fat diet and low-dose streptozotocin-induced diabetic rats.
Groups SOD (U/mL) CAT (U/mL) GSH-Px (μmole/gHb)
Normal control 8.39 ±0.02∗∗ 3.54 ±0.03∗∗ 0.00059 ±0.001∗∗
Normal STZ control 4.51 ±0.03 1.32 ±0.13 0.0038 ±0.001
HFD control 6.62 ±0.12∗∗ 2.10 ±0.01∗∗ 0.0042 ±0.002∗∗
HFD + STZ control 4.38 ±0.13 1.08 ±0.02∗∗ 0.00283 ±0.0017
CPQ (50mg/kg/day) 7.91 ±0.03∗∗ 2.80 ±0.16∗∗ 0.0048 ±0.003∗∗
CPQ (100mg/kg/day) 9.05 ±0.03∗∗ 3.31 ±0.01∗∗ 0.005 ±0.003∗∗
Curcumin (100mg/kg/day) 6.82 ±0.027∗∗ 2.57 ±0.02∗∗ 0.0049 ±0.001∗∗
Values are mean ± SEM; N = 6; ∗∗P<0.01 as compared to HFD + STZ control.
(a) (b)
(c) (d)
Figure 4: Histopathological structure of liver. (a) Control group animals; (b) diabetic group animals; (c) treated with CPQ at the dose of
100mg/kg of BW; (d) treated with curcumin at the dose of 100mg/kg of BW.
diabetes-induced animals, was signiﬁcantly elevated by the
administration of CPQ.
3.5. Histopathological Studies. Animals fed on high-fat diet
along with low-dose streptozocin diet appeared healthy and
showed no pathological sign of abnormalities during feeding
period of 8 weeks. Combination of high-fat diet and 30-
mg/kg body weight STZ produces mild changes in the
liver of diabetic rats showed degeneration and scattered
necrotic cells, multifocal mild degree per portal lymphocytic
inﬁltration, swollen cytoplasmic hydropic, and microvesic-
ular vacuoles were observed (Figure 4). However, treatment
with combination consisting of curcumin with piperine and
quercetin (CPQ) at doses of 100mg/kg decreased the gran-
ular degeneration in diabetic liver. None of the rats treated
with high-fat diet and streptozotocin or streptozotocin alone
noranyoftheuntreatedcontrolsdemonstratedeithergrossly
visible or microscopic renal abnormalities. No grossly visible
or microscopic abnormality was seen in the pancreas among
all groups of rats used in this study.
4. Discussion
It is widely considered that obesity threatens to become the
foremost cause of chronic disease in the world. Being obese
can induce multiple metabolic abnormalities that contribute
to obesity, dyslipidemia, cardiovascular disease, glucose
intolerance or type 2 diabetes and other chronic disorders
[20]. Despite the plethora of research data available on
obesity, it still remains; largely an unsolved medical problem.
Diet exercise and nutrition supplementation play a key role
in its prevention and treatment. Comparative bioavailability6 ISRN Pharmacology
studiesofcurcuminandcombinationconsistingofcurcumin
with piperine and quercetin (CPQ) were carried out in
rats under fed conditions, and the result shows signiﬁcant
increase in serum curcumin concentration on the inclusion
of piperine and quercetin in the CPQ. Hence in the present
study, we have isolated curcumin, piperine, and quercetin
from Curcuma longa Linn, Piper nigrum, and Allium cepa,
respectively and tested this combination consisting of cur-
cumin with piperine and quercetin (CPQ) compounds to
attenuate metabolic changes associated with high-fat diet
and low-dose streptozotocin-induced rats. Acute toxicity
study is carried out on laboratory animals by using high dose
(suﬃcient to produce death or morbidity) of the substance
in question and based on previous report on its toxicity
or toxicity of structurally related compounds. As there was
no previous report on toxicity of combination consisting of
CPQ, as per OECD guidelines, three dose levels starting at
500, 1000, and limit dose 2000mg/kg were selected for acute
toxicity study. The animals did not show any changes in
the general appearance during the observation period. There
was no signiﬁcant diﬀerence in body weight between control
and treatment groups. Food and water intake showed daily
ﬂuctuations but were within the range of control animals.
No mortality was observed in both control and in groups of
all selected dose levels.
Therefore, investigators have started to develop a rat
model by the combination of high-fat diet and low-dose
streptozocin (STZ) that would closely mimic the natural
history and metabolic characteristics of type 2 diabetes in
humans. Currently, many studies have reported that high-
fat diet feeding rats develop insulin resistance at ﬁrst, and
then an injection of a low dose of STZ at the same time
has been known to induce partial dysfunction of beta
cell for suppressing the insulin secretion, which works as
a compensation to insulin resistance with the result of
persistent hyperglycemia [21, 22].
The present study demonstrates that the rats when fed
with high-fat diet for 8 weeks combined with low-dose
streptozotocin resulted in signiﬁcant elevation of plasma
glucose as evident from elevated glycemic levels at 30, 60,
90, and 120min after glucose challenge, compared with the
vehicle-treated normal pellet diet (NPD) control group (P<
0.05) and exhibited the characteristic features of obesity and
glucose intolerance, namely, increased body weight, hyper-
triglyceridemia, hypercholesterolemia, and impaired glucose
tolerance compared with NPD fed control groups and is in
agreement with the ﬁndings of Buettner et al., (2000) [23].
In addition, HFD fed rats also showed signiﬁcant elevation
in plasma glucose and impairment in glucose tolerance to
exogenously administered glucose as compared with STZ
control rats. There are multiple mechanisms involved for the
development of insulin resistance and glucose intolerance
in high-fat diet fed rats. However, it could be hypothesized
that the nature of dietary fatty acid might be involved in
altering the cell membrane composition, thereby impeding
the binding of insulin to its receptor leading to signiﬁcant
increasein plasma glucoselevels in insulin-resistant HFD fed
ratswhencomparedwithNPDfednormalratsfollowinglow
dose of STZ (30mgkg−1, i.p.).
This is the ﬁrst study to show that the treatment of
the diabetic rats with CPQ resulted in marked decrease in
plasma glucose, triglycerides, total cholesterol, and LDL with
a concomitant increase in plasma HDL in HFD combined
with low dose STZ-induced diabetic rats. In addition, with
respect to the in vivo antioxidant enzymes, the pretreatment
withcombinationconsistingof“curcuminwithpiperineand
quercetin” (100mg/kg) once daily for 28 days had a potent
increasing eﬀect on serum glutathione and catalase activities,
along with elevating SOD activities compared to diabetic
group.
The antioxidative property of combinatorial extract cer-
tainly is due to its chemical constituents predominantly due
to the presence of phenolics which is reported in preliminary
phytochemical screening of CPQ. It is further supported
in literature that plant phenolics are well known for their
antioxidant activity. The phenolics in CPQ may thus play a
protective role againsttheoxidative damageto the pancreatic
beta cells. Beta cells are very susceptible to oxidative changes
since they possess a low antioxidative capacity [24, 25].
The results obtained strongly indicate that CPQ consisting
of “curcumin with piperine and quercetin” are important
sources of natural antioxidants as it signiﬁcantly (P<0.01)
prevented the high-fat diet and low-dose streptozotocin-
induced changes in the oxidative stress parameters.
Further development of glucose intolerance in HFD
combined with low-dose STZ-induced diabetic rats is also
in agreement with the data obtained in the literature
[26]. The criterion for the predictive diagnosis of diabetic
disease is based on the glyco-metabolic features. Here, we
investigate an OGTT test to observe the glycemic response
to exogenously administered glucose in diﬀerent groups of
rats after 8 weeks of dietary manipulation. The OGTT,
deﬁned as the “golden standard”, is a method of assessing
glucose tolerance and diagnosing diabetes mellitus. The
OGTT is advantageous as it is performed under rather
physiological conditions, as glucose is given per os thus
preserving the eﬀect of entero hormone response and the
physiological kinetics of glucose absorption [27]. In this
study, the decrease of blood glucose levels at given times
after glucose load indicated increased peripheral utilization
of glucose by combination consisting of “curcumin with
piperine and quercetin”. One possible mechanism of these
drugs to be eﬀective on postprandial blood glucose is due
to inhibition of α-glucosidase enzyme. It may also due to an
increase in insulin secretion by pancreas [28].
Treatment with CPQ decreased the granular degener-
ation and alleviated the histopathological changes caused
by diabetes in the liver of NIDDM rats. The literature
review clearly indicates that fatty inﬁltration of the aortic
subendothelium and deposition of fatin livers wereobserved
in diabetic rats induced by streptozotocin [29]. No special
renal abnormalities and pancreatic lesions in relation to any
of the high-fat diet could be established which could be due
to low dose of streptozocin used in the study. The curative
and preventive property of combinatorial extract in diabetic
rats may be due to its improvement in glucose tolerance and
antioxidant property.ISRN Pharmacology 7
5. Conclusion
In conclusion, the present data supports potent lipid
lowering action of combination consisting of “curcumin
with piperine and quercetin” in the HFD and low-dose
streptozotocin-induced diabetic rats thus further corrob-
orate its potential in the treatment of glucose tolerance
associated with excess dietary fat intake, obesity, and type
2 diabetes. Future work needs to be done in the direction
of use of CPQ for clinical studies with the aim to elucidate
the molecular and cellular mechanism involved with the
usage of these nutraceuticals for the prevention of metabolic
syndrome.
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